1 Harford WV. Gastrointestinal angiodysplasia: clinical features. Endoscopy. 1988;20(4):144–8.
2 Leighton JA, Goldstein J, Hirota W, Jacobson BC, Johanson JF, Mallery JS, et al. Obscure gastrointestinal bleeding. Gastrointest Endosc. 2003;58(5):650–5.
3 Boley SJ, DiBiase A, Brandt LJ, Sammartano RJ. Lower intestinal bleeding in the elderly. Am J Surg. 1979;137(1):57–64.
4 Orsi P, Guatti-Zuliani C, Okolicsanyi L. Long-acting octreotide is effective in controlling rebleeding angiodysplasia of the gastrointestinal tract. Dig Liver Dis. 2001;33(4):330–4.
5 Andersen MR, Aaseby J. Somatostatin in the treatment of gastrointestinal bleeding caused by angiodysplasia. Scand J Gastroenterol. 1996;31(10):1037–9.
6 Rossini FP, Arrigoni A, Pennazio M. Octreotide in the treatment of bleeding due to angiodysplasia of the small intestine. Am J Gastroenterol. 1993;88(9):1424–7.
7 Lecleire S, Iwanicki-Caron I, Di-Fiore A, Elie C, Alhameedi R, Ramirez S, et al. Yield and impact of emergency capsule enteroscopy in severe obscure-overt gastrointestinal bleeding. Endoscopy. 2012;44(4):337–42.
8 Foutch PG, Rex DK, Lieberman DA. Prevalence and natural history of colonic angiodysplasia among healthy asymptomatic people. Am J Gastroenterol. 1995;90(4):564–7.
9 Boley SJ, Sammartano R, Adams A, DiBiase A, Kleinhaus S, Sprayregen S. On the nature and etiology of vascular ectasias of the colon. Degenerative lesions of aging. Gastroenterology. 1977;72(4 Pt 1):650–60.
10 Sharma R, Gorbien MJ. Angiodysplasia and lower gastrointestinal tract bleeding in elderly patients. Arch Intern Med. 1995;155(8):807–12.
11 Franchini M, Togliani T, Turdo R, Lucchini G, Bonfanti C, Giacomini I, et al. O blood type is a risk factor for upper gastrointestinal bleeding. J Thromb Thrombolysis. 2018;45(1):48–50.
12 Becq A, Rahmi G, Perrod G, Cellier C. Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management. Gastrointest Endosc. 2017;86(5):792–806.
13 Vargo JJ. Clinical applications of the argon plasma coagulator. Gastrointest Endosc. 2004;59(1):81–8.
14 Zeller TC, Cissarek T, Gray WA, Kröger K. Gefässmedizin: Therapie und Praxis: ABW Wissenschaftsverlag; 2013.
15 Beg S, Ragunath K. Review on gastrointestinal angiodysplasia throughout the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2017;31(1):119–25.
16 Nardone G, Compare D, Martino A, Rocco A. Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis. 2018;50(6):542–8.
17 Jackson CS, Gerson LB. Management of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(4):474–83; quiz 84.
18 Morisset J. Somatostatin: One of the Rare Multifunctional Inhibitors of Mammalian Species. Pancreas. 2017;46(1):8–18.
19 Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm. 2003;18(4):601–9.
20 Pawlikowski M, Melen-Mucha G. Somatostatin analogs – from new molecules to new applications. Curr Opin Pharmacol. 2004;4(6):608–13.
21 Kumar N, Sharma U, Singh C, Singh B. Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity. Curr Top Med Chem. 2012;12(13):1436–55.
22 Randi AM. Endothelial dysfunction in von Willebrand disease: angiogenesis and angiodysplasia. Thromb Res. 2016;141 Suppl 2:S55–8.
23 Khatri NV, Patel B, Kohli DR, Solomon SS, Bull-Henry K, Kessler CM. Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease. Haemophilia. 2018;24(2):278–82.